Dr. Tagawa on Next Steps for Taxanes in Prostate Cancer

Scott T. Tagawa, MD
Published: Thursday, Mar 02, 2017



Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.

Although these results do not suggest changing from one particular taxane to the other, TAXYNERGY validated androgen receptor (AR) translocation as a mechanism of action of taxane chemotherapy, says Tagawa.

The next step is to use biomarkers to look at drug-target engagement in clinical trials, says Tagawa, which would hopefully determine the most effective AR plus a taxane combination for patients.
 
SELECTED
LANGUAGE


Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.

Although these results do not suggest changing from one particular taxane to the other, TAXYNERGY validated androgen receptor (AR) translocation as a mechanism of action of taxane chemotherapy, says Tagawa.

The next step is to use biomarkers to look at drug-target engagement in clinical trials, says Tagawa, which would hopefully determine the most effective AR plus a taxane combination for patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment DataApr 30, 20191.5
Community Practice Connections™: Personalized Assessment in Advanced RCC Decision Making: Leveraging the Evidence and Patient Characteristics to Inform Decisions Along the Disease ContinuumApr 30, 20191.5
Publication Bottom Border
Border Publication
x